Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. / Riesgo de infección asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biológicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevención.
Gastroenterol Hepatol
; 44(8): 587-598, 2021 Oct.
Article
en En, Es
| MEDLINE
| ID: mdl-33640469
ABSTRACT
Patients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Infecciones Bacterianas
/
Terapia Biológica
/
Virosis
/
Enfermedades Inflamatorias del Intestino
/
Inhibidores de las Cinasas Janus
/
Inmunosupresores
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
/
Es
Revista:
Gastroenterol Hepatol
Año:
2021
Tipo del documento:
Article